Over 12 months, aTYR PHARMA INC saw more buying than selling from its insiders — purchases of about $50,000 against sales of $6,293.
The largest purchase came from SCHIMMEL PAUL (Director), about $50,000.
Big money check: 90 institutions held ATYR as of Q2 2026, and more funds sold than bought. Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| May 28, 2026 | SCHIMMEL PAUL | Director | Buy | 100,000 | $0.50 | $50K | SEC |
| Feb 4, 2026 | Shukla Sanjay | CEO | Sell | 3,745 | $0.98 | $4K | SEC |
| Feb 4, 2026 | Broadfoot Jill Marie | CFO | Sell | 1,558 | $0.98 | $2K | SEC |
| Feb 4, 2026 | DENYES NANCY | Executive Officer | Sell | 1,118 | $0.98 | $1K | SEC |
| Oct 9, 2025 | SCHIMMEL PAUL | Director | Buy | 682,001 | $0.90 | $614K | SEC |
| Oct 9, 2025 | SCHIMMEL PAUL | Director | Buy | 317,999 | $0.94 | $299K | SEC |
| Mar 17, 2025 | Gross Jane A | Director | Buy | 3,750 | $4.00 | $15K | SEC |
| Feb 4, 2025 | Broadfoot Jill Marie | CFO | Sell | 1,254 | $3.78 | $5K | SEC |
| Feb 4, 2025 | DENYES NANCY | Executive Officer | Sell | 899 | $3.78 | $3K | SEC |
| Jul 24, 2024 | SCHIMMEL PAUL | Director | Buy | 41,052 | $1.74 | $71K | SEC |
| Jul 24, 2024 | SCHIMMEL PAUL | Director | Buy | 6,648 | $1.82 | $12K | SEC |
| Jul 24, 2024 | SCHIMMEL PAUL | Director | Buy | 52,300 | $1.93 | $101K | SEC |
| Jun 6, 2024 | DENYES NANCY | Executive Officer | Buy | 5,000 | $1.86 | $9K | SEC |
In the last 12 months aTYR PHARMA INC insiders made open-market purchases worth about $50,000 and sales worth about $6,293. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ATYR was filed on 2026-05-28.
90 investment managers reported holding ATYR in SEC Form 13F filings for Q2 2026.
No congressional trades in ATYR were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).